De novo bronchiectasis in haematological malignancies: patient characteristics, risk factors and survival

Bronchiectasis occurs de novo in haematological malignancy and is associated with significant mortality and morbidity. Rituximab predisposes to IgG deficiency and survival time is significantly associated with age, FEV(1) % and stem cell transplantation. http://bit.ly/2KZwCZt

Detalles Bibliográficos
Autores principales: José, Ricardo J., Hall, Jocelin, Brown, Jeremy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Original Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826250/
https://www.ncbi.nlm.nih.gov/pubmed/31720297
http://dx.doi.org/10.1183/23120541.00166-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826250/
https://www.ncbi.nlm.nih.gov/pubmed/31720297
http://dx.doi.org/10.1183/23120541.00166-2019

Ejemplares similares